CSPC Pharmaceutical Group (HKG:1093) subsidiary, CSPC Megalith Biopharmaceutical, signed an exclusive licensing agreement with Radiance Biopharma for the development and commercialization of the Group's SYS6005 in the US, UK, and several other parts of the world, according to a Wednesday filing with the Hong Kong bourse.
CSPC Megalith will get an initial payment of US$15 million. The pharmaceutical may also receive potential development and regulatory milestone payments of up to US$150 million and potential sales milestone payments of up to US$1.08 billion, with a possibility of tiered royalties based on annual net sales of the Product in the Territory.
This drug uses a special enzyme-based technology to attach a powerful cancer-killing agent (MMAE) to an antibody, targeting cancer cells that have a protein called ROR1.
Other areas in the contract include Switzerland, Norway, Iceland, Liechtenstein, Albania, Montenegro, North Macedonia, Serbia, Australia, and Canada.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。